Clinical Trials · NCT04878406

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
24
Start date
May 2021
Locations
1 site, Japan
Primary endpoint
Number of treatment emergent adverse events (TEAEs)
View Semaglutide compound reference